June 3rd 2013
Shortages of cancer drugs caused many oncologists and hematologists to choose suboptimal treatment plans for their patients last year, and government efforts have done little to boost the availability of the hard-to-find medications.
Interim findings from a randomized, global, phase III study indicate that the multi-targeted drug sorafenib nearly doubled PFS for patients with differentiated thyroid cancer resistant to radioactive iodine therapy.
June 2nd 2013
An oral targeted drug already approved by the FDA for the treatment of kidney cancer and soft tissue sarcoma has been found to extend disease-free survival in women with advanced ovarian cancer.
May 22nd 2013
The SGO asserts that women with gynecologic cancers frequently receive uncoordinated, fragmented testing and treatment from multiple providers at a variety of sites, often without the involvement of a specialist or supportive services.
May 15th 2013
Radiotherapy at a higher-than-standard dose is harmful to patients with locally advanced non-small cell lung cancer who are also getting concurrent and consolidation chemotherapy.
May 9th 2013
Several case studies highlighting the latest strategies and therapeutic agents available for patients with prostate cancer.
May 8th 2013
The strategy of targeting aberrant signaling in the JAK pathway appears promising thus far for SAR302503, an oral agent in development for the treatment of myelofibrosis.
May 3rd 2013
An interview with Alice Tsang Shaw, MD, PhD, who has won broad recognition for her contributions to the treatment of NSCLC, including the use of crizotinib to target the ROS1 gene rearrangement and research into other emerging agents.
May 2nd 2013
Citing concerns about the safety profile of the device, ODAC unanimously recommended against the approval of the Melblez chemosaturation system for use with melphalan hydrochloride in the treatment of patients with ocular melanoma metastasized to the liver.
May 1st 2013
Experts provide an in-depth look at the treatment strategy in patients with solid tumors, specifically looking at the role of maintenance therapy.
April 12th 2013
An interview with José Baselga, MD, PhD, who helped to develop new drugs and combination therapies for the treatment of breast cancer, including the early targeted therapy trastuzumab and the more recent pertuzumab.
April 9th 2013
Follicular lymphoma is characterized by repeated treatment responses and then relapses, and until more effective frontline therapies become available, researchers will need to generate a growing list of drug choices to keep pace with patients' needs.
José Baselga, MD, PhD, explores the dual inhibition of cell-signaling pathways in breast cancer on several fronts, including new therapies for patients with the HER2-positive subtype and novel ways to target mTOR and the PI3K/Akt/mTOR pathway.
April 8th 2013
Sign-toting scientists, students, patients, and caregivers gathered near the Carnegie Library in Washington, DC, to protest recent cuts to the budget of the National Institutes of Health, the largest funder of medical research in the world.
March 28th 2013
While there is no standard treatment for most patients with chronic lymphocytic leukemia who are age 65 years and older, several regimens are being tested in clinical trials.
March 25th 2013
Two novel, oral drugs that target the B-Cell receptor signal transduction pathway could significantly change the way chronic lymphocytic leukemia is treated.
March 22nd 2013
15 years after treatment, patients have roughly equal odds of experiencing declines in functions, with no significant difference associated with their choice of either radical prostatectomy or external-beam radiation therapy.
March 18th 2013
Following the recent flurry of FDA approvals for prostate cancer medications, oncologists are grappling with questions about which combinations or sequences of those therapies might improve outcomes for patients.
March 12th 2013
The multidisciplinary clinic for patients with prostate and other GU cancers at Thomas Jefferson University Hospital has served as a model for other departments interested in providing multidisciplinary care.
March 11th 2013
Working in the laboratory and the clinic, Shaji K. Kumar, MD, has made a discovery: that there aren't enough hours in a day.